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Abstract 
Background. Although uncommon, snakebites can cause significant morbidity and mortality.  
The objective of this study was to review the characteristics, treatment, and outcome of patients 
with a suspected or known snakebite who were treated at a regional verified burn center. 
Methods. A retrospective chart review of all snakebite victims was conducted for the time frame 
between January 1991 and June 2009. 
Results. During the study period, 12 patients were identified. One of the twelve patients was 
excluded because he had been admitted as an outpatient for wound debridement after being 
initially treated at another facility. Ten of the remaining 11 patients were male (90.9%).  
Rattlesnakes were responsible for the majority of bites. One of the eleven patients needed a 
fasciotomy. The majority of patients received antivenin (ACP/fabAV). No anaphylactoid 
reactions to either antivenin were recorded. There were no deaths. 
Conclusion. With burn centers evolving into centers for the care of complex wounds, patients 
with snakebite injuries can be managed safely in a burn center. 
KS J Med 2013; 6(2):44-50. 
 
 
Introduction 
Snakebites, although rare, can be life-
threatening. Between 5,000 to 7,000 
venomous snakebites occur annually in the 
United States.
1,2
 From one to six deaths 
occur per year in the United States from 
envenomation.
3-5
 Snake venom can cause 
local tissue damage, neurotoxicity, and non-
specific systemic effects. Systemic reactions 
can lead to disorders in coagulation, acute 
renal failure, hypovolemic shock, and death. 
The purpose of the current study was to 
review the characteristics and outcomes of 
all snakebite victims admitted to a regional 
medical center. The standard practice is to 
admit these patients to the American Burn 
Association verified regional burn center 
with care provided by designated burn and 
wound care surgeons. 
 
Methods 
Study design, setting, and selection of 
participants.      A retrospective chart review 
 
was conducted of all patients admitted to a 
regional health center for the treatment of a 
snakebite between January 1991 and June 
2009.   
Data collection and analyses. Patient 
medical records were reviewed for 
demographics, location and number of 
snakebites, type of snakebite, mode of 
arrival, patient presentation, antivenin 
treatment, antibiotic treatment, tetanus 
history, wound care treatment and surgical 
interventions, complications, and outcomes.  
Data summaries were calculated using SPSS 
release 16.0 (IBM Corp., Somers, New 
York). 
This study was approved for 
implementation by the Institutional Review 
Board of Via Christi Hospitals Wichita, Inc. 
and the Human Subjects Committee of the 
University of Kansas School of Medicine-
Wichita. 
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Results 
During the study period, 12 patients 
meeting stated criteria were identified.  
However, one of these patients had been 
admitted as an outpatient for wound 
debridement and split thickness skin graft 
after initial treatment at another facility and 
was excluded from the study outcome 
measurements. Of the remaining 11 
subjects, the majority was male, Caucasian, 
and their average age was 33.5 years (Table 
1). One patient (9.1%) under the age of 18 
was identified. Nearly one-half of the 
patients were transported by air to the 
facility (45.5%). 
Of the 11 patients with snakebites, five 
were the result of rattlesnake bites (Table 2).  
Type of snake was unknown in three 
patients (27.3%), however, in two, 
rattlesnakes were suspected. If true, then 
rattlesnakes were responsible for 7 of the 11 
envenomations (63.6%). The majority of 
patients sustained one snakebite (81.8%).  
Of the 14 bites sustained, the majority were 
located on the hand (64.3%). Of the two 
patients that sustained multiple bites, one 
sustained two bites to the hand and one 
sustained two bites to the hand and one to 
the forearm. Therefore, of the 14 bites, 
78.6% were located on upper extremities 
and 21.4% on lower extremities. 
Ten patients (90.9%) were bitten 
between the months of April and September.  
Two of the patients (18.2%) were owners of 
the snakes that bit them. Four 
envenomations (28.6%) involved intentional 
interaction with the snake, and nine 
envenomations (81.8%) occurred while the 
patient was outside. The action was 
uncertain in one patient’s case, but the bite 
was from a pet copperhead snake. Three 
patients (27.3%) had consumed alcohol prior 
to being bitten. 
Pre-hospital treatment was documented 
for four patients (36.4%). Two were self-
treatments and the remaining treatments by 
 
EMS. Of the two self-treated cases, one 
patient used his belt as a tourniquet and 
another attempted to “suck” the venom from 
her thumb. Of the two cases treated by EMS, 
both had some form of a tourniquet applied, 
and one had ice packs placed over the 
wound. 
Nine patients (81.8%) received antivenin 
(Table 3), of which six received ovine 
polyvalent Crotalidae antivenom (FabAV) 
and two received equine antivenin 
Crotalidae polyvalent (ACP).  In one patient, 
the type of antivenin administered was not 
documented clearly. Of the patients 
receiving FabAV, an average of 10 ± 6 vials 
was given. For patients receiving ACP, one 
was administered 6 vials, and the other 20 
vials. Of the two patients who did not 
receive antivenin treatment, one case was at 
the request of the patient’s family. The other 
patient who did not receive antivenin had a 
local reaction to a test dose of equine ACP 
and was not given the antivenin. No 
anaphylactic reactions to the antivenins were 
recorded. 
All patients had their tetanus status 
checked and were updated as indicated by 
standard guidelines. Five of the 11 patients 
(45.5%) were given prophylactic antibiotics 
during their treatment course (Table 3). Of 
the six patients who did not receive 
antibiotics, one returned for an incision and 
drainage for an abscess, and subsequently 
was prescribed antibiotics.   
A teen male bitten just above the 
Achilles tendon required a fasciotomy for 
clinically diagnosed compartment syndrome. 
Three complications were noted including 
one patient with compartment syndrome and 
another with a bite infection. The final 
patient was readmitted, after leaving against 
medical advice, with a gastrointestinal (GI) 
bleed, secondary to suspected disseminated 
intravascular coagulation several days after 
the snakebite injury. 
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Table 1. Patient demographics and transport mechanism. 
*Mean ± standard deviation (range) 
 
Table 2. Snake bite characteristics. 
Parameter Number Percent 
Type of snake involved   
     Rattlesnake 5 45.5% 
     Copperhead 3 27.3% 
     Unknown 3 27.3% 
Number of snake bites   
     1 9 81.8% 
     2 1 9.1% 
     3 1 9.1% 
Location of snake bites   
     Hand 9 64.3% 
     Forearm 2 14.3% 
     Lower leg 2 14.3% 
     Foot 1 7.1% 
 
Table 3. Treatments administered hospitalization characteristics and mortality. 
Parameter Number Percent 
Antivenin administered 9 81.8% 
Antibiotics administered 5 45.5% 
Infection 1 9.1% 
Surgical intervention 2 18.2% 
Burn center admission 10 90.9% 
Required mechanical ventilation 1 9.1% 
Burn Center length of stay, days 10 3.5 ± 2.7 
Hospital length of stay, days 11 4.2 ± 2.7 
Mortality 0 0.0% 
Parameter Number Percent 
Number of subjects 11 100% 
Mean age, years 11 33.5 ± 10.9 (12 – 45)* 
Male sex 10 90.9% 
Race   
     Caucasian 8 72.7% 
     Hispanic 2 18.2% 
     Unknown 1 9.1% 
Transport method   
     Air 5 45.5% 
     Private vehicle 3 27.3% 
     Ground Emergency Medical Services (EMS) 3 27.3% 
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Ten of the 11 patients (90.9%) were 
admitted to the burn center with an average 
length of stay of 3.5 days (Table 3).  
Average hospital stay was 4.2 days. There 
were no deaths and all patients were 
discharged to home. 
 
Discussion 
General. The findings in this case series 
are similar to those in other studies. The 
majority of the snakebite victims in prior 
reports were also male (66.6-100%).
6-10
  One 
study found most bites (67%) resulted from 
intentional exposure and 40% of snakebite 
victims had consumed some amount of 
alcohol prior to the bite.
11
 Mortality from 
snakebites has been reported between 0-
0.21%.
1,2,8,9
 The average hospital length of 
stay for patients in various studies ranged 
from 2.8 to 5.6 days.
9,12,13
 Tokish et al.
12
 
reported that 36% of patients were 
transported by air. 
The majority of snakebites (84-94%) 
occurred between the months of April and 
September.
1,2,12,14
 Most injuries, 95-100% of 
bites, occurred on the extremities.
10,14
  
Parish
1 
reported the majority of bites in the 
lower extremities (58%). 
All of the snakes identified in our study 
were types of viperids (rattlesnakes and 
copperheads). No coral snakes (elapids) 
were identified as the culprit in this study.  
This finding is most likely geographically 
related. Crotalidae snakes, the subfamily of 
viperids that includes the rattlesnakes, 
copperheads, and cottonmouths, also were 
found as the most common cause of 
snakebites from the database of the 
American Association of Poison Control 
Centers (98% viperid; 2% elapids).
2
 
Prehospital care. Tokish et al.
12
 found 
that 18% of snakebite patients received 
some sort of first aid prior to presenting to 
their facility. The methods included “cut and 
suck”, cryotherapy, tourniquet, and 
superficial constriction band. Cryotherapy 
lead to extensive soft-tissue necrosis when 
compared to no treatment.
15
 No improve-
ment in survival or outcome with incision 
and suction has been shown in humans
16
 and 
there is no evidence that lymphatic 
constriction bands (flat, wide bands applied 
only to block superficial venous and 
lymphatic flow, but loose enough to admit 
1-2 fingers) provide any treatment benefit. 
In our series, none of the patients that 
employed cryotherapy, tourniquet/super-
ficial constriction band, or local wound 
suction required surgical intervention or had 
complications, although all of these 
therapies were discontinued in the 
emergency department. 
Antibiotics. Antibiotic usage in our 
study (46%) was slightly higher than that 
reported by Nazim (36%).
10
 In our series of 
patients, antibiotics were administered as 
prophylaxis, however, wound infections 
after crotalid envenomation have been 
reported to occur in approximately 3% of 
cases, therefore, it is recommended that 
antibiotics only be given when clinical and 
microbiologic evidence of wound infection 
is present.
14,17
 
Surgical interventions. Approximately 8 
to 28% of snakebite patients require surgical 
intervention, with the majority requiring 
fasciotomy (4 to 15.6% of all snakebite 
patients).
9,10,12,13
 Only one of our patients 
(9%) required a fasciotomy, for elevated 
compartment pressures. For patients with 
elevated compartment pressures, Gold et 
al.
18
 recommended an additional 4-6 vials of 
FabAV over an hour should be 
administered. 
Antivenin. Antivenin Crotalidae Poly-
valent (ACP) was introduced in 1954. It is 
comprised of immunoglobulins isolated 
from horse serum after exposure to Crotalus 
atrox (Western diamond rattlesnake), 
Crotalus adamanteus (Eastern diamond 
rattlesnake), Crotalus durissus terrificus 
(Tropical rattlesnake, Cascabel), and 
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Bothrops atrox (“Fer-de-lance”). It has not 
been distributed since 2002 and all United 
States stocks were to have expired as of 
March 2007.
14,19
 Rates for acute allergic 
reactions (including hypotension and 
anaphylaxis) ranged from 23-56% for 
ACP.
17 
FabAV was introduced in 2000.
14
 It is 
purified Fab fragments of sheep 
immunoglobulin after exposure to Crotalus 
atrox (Western diamondback rattlesnake), 
Crotalus adamanteus (Eastern diamondback 
rattlesnake), Crotalus scutulatus (Mojave 
rattlesnake), and Agkistrodon piscivorus 
(cottonmouth or water moccasin).
19
 The 
incidence of acute reaction with FabAV 
have been reported at 14.3%, and nearly all 
events were mild to moderate.
17
  
Contraindications to FabAV include a 
known hypersensitivity to papaya or papin. 
Beside the differences in acute allergic 
reactions, fewer fasciotomies with FabAV 
(9%) than with ACP (24%) have been 
documented.
9
 Recommended dosing for 
FabAV are 4-6 vials to achieve initial 
control, with an additional 4-6 vials until 
control of symptoms is reached. After initial 
control is reached, two vials at 6, 12, and 18 
hours are recommended to prevent recurrent 
toxicity.
20
 In a review of our patients, the 
indication and timing of the doses were 
similar to the previously mentioned strategy.  
The ovine FabAV has a relatively short half-
life of 12-30 hours. 
Treatment recommendations. Prehos-
pital treatment should include avoiding 
excessive activity, immobilizing the bitten 
extremity, and quickly transporting the 
victim to the nearest hospital.
17
 Initial 
hospital management includes managing the 
airway, evaluation of breathing and 
circulation, providing supportive care, 
cleaning of the wound, consultation with a 
medical toxicologist if needed prior to 
antivenin administration, and providing 
tetanus toxoid or tetanus immunoglobulin if 
indicated.
17
 Patients with moderate to severe 
toxicity after Crotalinae bites, or confirmed 
rattlesnake or water moccasin (cottonmouth) 
bites and minimal toxicity should receive 
FabAV.
19
 
Patients with confirmed copperhead 
bites and minimal toxicity should not 
receive FabAV. Copperhead bites are not 
considered to be as toxic as cottonmouth or 
rattlesnake bites.
13,14
 A report of 60 patients 
with copperhead bites treated without 
antivenin or surgery did not lead to any 
death, infection, tissue loss, or compartment 
syndromes.
21
 
Patients should be monitored for any 
acute reactions. Epinephrine, diphen-
hydramine, cimetidine, inhaled albuterol, 
and intravenous corticosteroids should be 
readily available.
17
 Patients should be 
monitored for compartment syndrome and 
should be confirmed with compartment 
pressure measurements. Antibiotics are 
generally not recommended. Patient’s 
laboratory values should be monitored for 
coagulopathy and rhabdomyolysis.  
In some hospitals, all snakebite patients 
are admitted to an intensive care unit (ICU) 
for monitoring, regardless of treatment with 
antivenin, although one case review 
suggested that the ICU is overused for the 
treatment of snakebite patients.
12
 It is 
standard policy in this institution for all 
snakebite patients to be admitted to the burn 
center, in which all beds are ICU capable.  
With many burn centers evolving into 
complex wound centers, patients with 
snakebite injuries may represent another 
group that can be provided appropriate care 
in that setting.
22
  
Limitations. This study is subject to the 
limitations inherent to all retrospective 
studies: reliance upon data as recorded at the 
time of patient care, lack of specific details, 
and possible recording inaccuracies. 
Another limitation of this study was no 
standard grading scale for assessment of 
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envenomation. Additionally, this investi-
gation suffered from a relatively small 
sample size, limiting the validity of any 
conclusions drawn from the data. 
 
Conclusions 
Guidelines for snakebites, such as used 
in our institution, may be beneficial as they 
represent an uncommon injury. The 
guidelines should include a grading scale for 
the assessment of envenomation to avoid the 
unnecessary use of FabAV. With many burn 
units across the country accepting non-burn 
patients, including patients with complicated 
wounds, those with snakebite injuries can be 
monitored and managed effectively in a burn 
unit. Furthermore, the presence of burn 
trauma surgeons can facilitate surgical 
intervention for compartment syndrome 
and/or the need for debridement and wound 
closure.
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